• Eli Lilly and Co., of Indianapolis, and Kowa Pharmaceuticals America Inc., of Montgomery, Ala., reported results from the PREVAIL (Pitavastatin compaREd with praVAstatin in Lowering LDL-C in the U.S.) study, which showed that Livalo (pitavastatin) 4 mg had superior LDL-C reduction compared with pravastatin 40 mg after 12 weeks of therapy. Data for secondary endpoints showed that Livalo reduced apoliprotein B, non-HDL-C and total cholesterol compared with pravastatin and improved high-density lipoprotein cholesterol and triglycerides. Those results were presented at the National Lipid Association's Scientific Sessions in Scottsdale, Ariz.